Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
Status:
Terminated
Trial end date:
2019-08-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib. The
trial is open-ended, which means patients will continue to take rociletinib until the study
doctor determines it is no longer beneficial for them.